|Bid||9.15 x 0|
|Ask||9.19 x 0|
|Day's Range||8.97 - 9.68|
|52 Week Range||4.06 - 18.37|
|Beta (3Y Monthly)||-3.08|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cresco Labs Inc. (“Cresco Labs”) (CL.CN) (CRLBF) and CannaRoyalty Corp. d/b/a Origin House (“Origin House” and together with Cresco Labs, the “Companies” – CSE: OH, OTCQX: ORHOF), both announced today that, effective September 16, 2019, they have each submitted certifications of substantial compliance with the request for additional information (“Second Request”) from the United States Department of Justice Antitrust Division (the “DOJ”) in connection with Origin House’s and Cresco Labs’ notification to U.S. antitrust authorities pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”), as amended, in respect of Cresco Labs’ pending acquisition of Origin House (the “Transaction”).
Tryke generated US$70.4 million in Revenue and US$24.6 million in EBITDA in fiscal 20181, making it one of the highest grossing and most profitable private cannabis companies in the U.S. market. Arizona is one of the largest and fastest growing medical-only markets with estimated 2019 sales of up to US$760 million 2 . Tryke has established six of the best-positioned retail locations in Nevada and Arizona, including the iconic Reef Dispensary located adjacent to the Las Vegas Strip and five additional operating locations in North Las Vegas, Sparks and Phoenix, AZ.
Tryke generated US$70.4 million in Revenue and US$24.6 million in EBITDA in fiscal 20181, making it one of the highest grossing and most profitable private cannabis companies in the U.S. market. Arizona is one of the largest and fastest growing medical-only markets with estimated 2019 sales of up to US$760 million 2. Tryke has established six of the best-positioned retail locations in Nevada and Arizona , including the iconic Reef Dispensary located adjacent to the Las Vegas Strip – which has produced over US$65 million in revenue since 2015 – and five additional operating locations in North Las Vegas , Sparks and Phoenix, AZ.
Cowen analyst Vivien Azer initiated coverage Friday of five multi-state cannabis operators, saying she's bullish on those that rely on the consumer packaged goods model given the higher margins, especially relative to those relying on the retail model. Azer started Green Thumb Industries Inc. at outperform with a stock price target of $18.50, Curaleaf Holdings Inc. at outperform with a $10.50 target, and Cresco Labs Inc. at outperform with a $14 target. "We believe that the greatest shareholder value will be created through businesses that emulate a traditional CPG finished goods model, given its superior margin structure," Azer wrote in a note to clients. Meanwhile, Azer started MedMen Enterprises Inc. at underperform with a $1.50 price target. "[MedMen] is the clear leader in the [California] market, with a distinguished brand, reflecting an attractive retail concept," Azer wrote. "However, to us, retail is less attractive than wholesale. And, an over-reliance on retail revenues today, coupled with excessive spending and notable management turnover, make this a'show-me' story." Azer also started Acreage Holdings Inc. at market perform with a $9 target, saying consolidation a of a "disparate network of dispensaries" and launching a "nascent brand strategy" could prove challenging. The ETFMG Alternative Harvest ETF was up 0.4% in afternoon trading, but has lost 28.7% over the past three months, while the S&P 500 has gained 3.5% in three months.
Conference Call with Investors and Analysts to be Held at 5:00 p.m. Eastern Time Today
Toronto, Ontario--(Newsfile Corp. - August 20, 2019) - Capital 10X sits down with Cresco Labs (CNSX: CL) President Joe Caltabiano for a pre-earnings review of the multi-state operator's expansion.Cannot view this video? Visit:https://capital10x.com/interview-cresco-labs-joe-caltabiano-pre-earnings-review/Joe talks about the recent Sunnyside* retail rollout, current and future acquisitions, and Cresco Labs' strategy as they continue to grow into one of top U.S. cannabis companies.For more information, please contact:Capital 10XEvan Veryard, President416-571-9037To view the source version of ...
“We are pleased to further expand access to Cresco Labs shares with our listing on the Frankfurt Stock Exchange,” said Cresco Labs CEO & Co-Founder Charlie Bachtell. The Frankfurt Stock Exchange is the largest exchange in Germany and one of the largest markets for trading equity securities in the world.
Cresco Labs Inc. (“Cresco Labs” or the “Company”) (CL.CN) (CRLBF), one of the largest vertically integrated multistate cannabis operators in the United States, today provided comments on the signing into law of legislation that makes Illinois’ medical-use cannabis program permanent, expands the list of qualifying medical conditions, and allows for nurse practitioners and physician’s assistants to certify a patient’s eligibility for the program in addition to doctors. The new law signed by Illinois Governor JB Pritzker on August 12, 2019 takes effect immediately and adds debilitating illnesses such as chronic pain, migraines and irritable bowl syndrome to the list of qualifying medical conditions. Cresco Labs CEO & Co-Founder Charlie Bachtell commented, “We have seen incredible growth in the Illinois medical cannabis program in 2019 with the number of registered patients increasing by more than 50% since the start of the year.
Cresco Labs Inc. (“Cresco Labs” or the “Company”) (CL.CN) (CRLBF), one of the largest vertically integrated multistate cannabis operators in the United States, today announced that it has received regulatory approval for its acquisition of 100% of the membership interests of Gloucester Street Capital, LLC (“Gloucester”), the parent entity of Valley Agriceuticals, LLC ("Valley Ag") via a merger between Gloucester and an indirect subsidiary of Cresco Labs. Valley Ag holds one of the 10 vertically integrated cannabis business licenses granted in the State of New York by the New York State Department of Health.
Cresco Labs Inc. (“Cresco Labs” or the “Company”) (CL.CN) (CRLBF), one of the largest vertically integrated multistate cannabis operators in the United States, will report its financial results for the second quarter ended June 30, 2019 on Wednesday, August 21, 2019 after the market closes. The Company will hold a conference call and webcast to discuss its business and financial results on Wednesday, August 21, 2019 at 5 p.m. Eastern Time (4 p.m. Central Time). The conference call may be accessed via Cresco Labs’ investor relations website at investors.crescolabs.com or by dialing 866-688-4235 (409-216-0711 for international callers) and providing conference ID 3385937.
Cresco Labs, Inc. (CL.CN) (CRLBF) (“Cresco” or “the Company”) one of the largest vertically integrated multistate cannabis operators in the United States, today announced that Charlie Bachtell, CEO & Co-Founder, and Joe Caltabiano, President & Co-Founder, will participate in the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, 2019 in Boston. The Company’s presentation is scheduled for 9:30 a.m. ET / 6:30 a.m. PT. Cresco Labs, based in Chicago, is a leading U.S. cannabis company with experienced management, access to capital and a demonstrated growth strategy.
Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the ...
If you have doubts that cannabis is on its way from illegal to industrial, take a look inside Cresco Labs’ custom built, 43-thousand square-foot production facility in Joliet, Illinois.
Cresco Labs Inc. (“Cresco Labs” or the “Company”) (CL.CN) (CRLBF), one of the largest vertically integrated multistate cannabis operators in the United States, today provided an update on its Illinois operations following Governor JB Pritzker’s signing into law of the legalization of adult-use cannabis in Illinois beginning on January 1, 2020. “The legalization of adult-use cannabis and the recent expansion of the state’s medical-use program are expected to dramatically increase the consumer base in Illinois and result in annual sales of $2 billion to $4 billion as the market matures,” said Cresco Labs CEO & Co-Founder Charlie Bachtell. “We are making excellent progress on our plans to serve the expanded consumer base, maintain our market leading position in Illinois, and capitalize on the significant growth opportunities available to Cresco.